| Clear Cell Adenocarcinoma studied in …STUDIED_INderived200 of 362show all (up to 200) |
|---|
| → studied in | NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03348631Phase 2 · active not recruiting Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Bladder Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07011719Phase 3 · recruiting Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07671417early Phase 1 · recruiting Imaging Study in Metastatic Clear Cell RCC. · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07770802Phase 1 · recruiting Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04071223Phase 2 · active not recruiting Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05112601Phase 2 · recruiting Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07594106Phase 1/Phase 2 · recruiting REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07748988Phase 1 · recruiting Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07840001Phase 2 · not yet recruiting Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04810078Phase 3 · active not recruiting A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06863311Phase 2 · recruiting Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07833085NA · not yet recruiting CAIX-targeted PET/CT in Solid Tumors · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07688187Phase 1 · recruiting A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07828249Phase 1 · not yet recruiting Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06916624recruiting Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07227415Phase 1/Phase 2 · recruiting Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07576725Phase 2 · not yet recruiting Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02974738Phase 1 · active not recruiting A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07718854Phase 2 · recruiting Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04575935Phase 3 · recruiting Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04977453Phase 1/Phase 2 · recruiting GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05012371Phase 2 · active not recruiting Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07516366Phase 2 · recruiting Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06708949Phase 2 · active not recruiting A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02101775Phase 2 · active not recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02496208Phase 1 · active not recruiting Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06480565Phase 1/Phase 2 · active not recruiting A Phase 1/2 Trial of ADI-270 in ccRCC · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00977574Phase 2 · active not recruiting Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07256223Phase 2 · not yet recruiting A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07188896Phase 2 · recruiting A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05950464Phase 1 · recruiting Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06661720Phase 3 · recruiting Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03793166Phase 3 · active not recruiting Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05536141Phase 1 · recruiting A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02142803Phase 1 · active not recruiting TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02839707Phase 2/Phase 3 · active not recruiting Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02068794Phase 1/Phase 2 · active not recruiting MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03355976Phase 2 · active not recruiting BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07123090Phase 2 · recruiting A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07187778Phase 2 · recruiting Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE) · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07776717Phase 2 · not yet recruiting TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05361720Phase 2 · recruiting Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07768306Phase 1 · not yet recruiting Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05231122Phase 2 · recruiting Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01038778Phase 1/Phase 2 · active not recruiting Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02978625Phase 2 · active not recruiting Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Hidradenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05706129Phase 1/Phase 2 · recruiting A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06242470Phase 1 · recruiting A Study of MGC026 in Participants With Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07187869Phase 1 · recruiting Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07615348Phase 2 · recruiting CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01575548Phase 3 · active not recruiting Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05046080recruiting Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05226507Phase 1 · terminated A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05581004Phase 1 · active not recruiting A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05176483Phase 1 · recruiting Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07226544Phase 2 · recruiting Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739800Phase 2 · active not recruiting Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05433142Phase 1 · recruiting Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07000149Phase 1 · active not recruiting A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07300241Phase 1 · recruiting Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03284385Phase 2 · active not recruiting Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03914612Phase 3 · active not recruiting Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06866262Phase 1/Phase 2 · recruiting Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05663710Phase 1/Phase 2 · recruiting Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07179770Phase 1 · recruiting Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC) · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05665361Phase 1/Phase 2 · recruiting Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07564232Phase 1 · recruiting Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05460000Phase 2 · recruiting A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07043608Phase 2 · recruiting Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06942104Phase 1 · recruiting Imaging of Solid Tumors Using 18F-TRX · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06049576Phase 1 · active not recruiting Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03120624Phase 1 · active not recruiting VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07077083Phase 2 · not yet recruiting CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04092270Phase 1 · active not recruiting A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04719273Phase 2 · completed Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07128680Phase 1 · recruiting Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04374877Phase 1 · completed Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03972657Phase 1/Phase 2 · recruiting A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06339138completed Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05520099active not recruiting Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02) · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00326898Phase 3 · completed Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02848768completed Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02834013Phase 2 · active not recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06447103Phase 2 · recruiting An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07383441Phase 3 · recruiting Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07037004Phase 2 · recruiting Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06026410Phase 1 · recruiting KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07510334Phase 2 · recruiting VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06783348Phase 2 · recruiting Radiopharmaceutical Treatment of Advanced Kidney Cancer · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03092856Phase 2 · active not recruiting Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00951496Phase 3 · completed Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06730347Phase 2 · recruiting A Study of Lorigerlimab in Participants With Advanced Solid Tumors · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Vaginal Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02210117early Phase 1 · active not recruiting Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05039801Phase 1 · recruiting IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06090331no longer available 89Zr-DFO-girentuximab Expanded Access Program (EAP) · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06949215Phase 2 · recruiting 68Ga-NYM096 PET/ CT for the Detection of ccRCC in Presurgical Patients With Complex Cystic Renal Leision · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07023432Phase 2 · recruiting Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC) · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07602101Phase 2 · not yet recruiting Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04388852Phase 1 · active not recruiting DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06035224Phase 2 · active not recruiting Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07557225NA · recruiting 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06852638Phase 2 · recruiting CD70-targeted immunoPET Imaging of Malignant Cancers · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06195150active not recruiting Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07571551Phase 2 · recruiting Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07578025Phase 2 · not yet recruiting Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06708936early Phase 1 · withdrawn KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory Clinical Study · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02535533Phase 1/Phase 2 · completed SLM + Axitinib for Clear Cell RCC · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04053855recruiting Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05049538recruiting Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06023862Phase 2 · recruiting A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04022343Phase 2 · active not recruiting Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01737619NA · active not recruiting PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07072234Phase 1 · recruiting Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06413680Phase 1/Phase 2 · recruiting A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06059014Phase 1/Phase 2 · completed Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03682289Phase 2 · active not recruiting Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02874430Phase 2 · terminated Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06138496Phase 2 · completed Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03401788Phase 2 · active not recruiting A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Von Hippel Lindau Syndrome-Associated Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07197580Phase 3 · recruiting Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02122185Phase 2 · completed Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04919629Phase 2 · recruiting APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07488572Phase 2 · enrolling by invitation Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04904302Phase 2 · terminated Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05500391Phase 2 · recruiting Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07469683Phase 2 · recruiting An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06349642recruiting Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07460206Phase 2 · not yet recruiting Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06860386Phase 2 · suspended Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05122546Phase 1 · active not recruiting CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07223541Phase 2 · recruiting Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01684397Phase 1/Phase 2 · active not recruiting Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07243067not yet recruiting Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06964958Phase 2 · active not recruiting 177LuPSMA in Renal Cell Carcinoma · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06716853Phase 1/Phase 2 · terminated A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01625351Phase 1 · completed A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07389629Phase 2 · recruiting Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07386158Phase 2 · recruiting Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04645680Phase 2 · active not recruiting Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04623502NA · recruiting An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05239533Phase 2 · active not recruiting Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06840548Phase 1 · completed A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07332923active not recruiting Predicting HIF-2α Levels in Clear Cell Kidney Cancer Using Machine Learning · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06649682Phase 1 · suspended 68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00565851Phase 3 · active not recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05856981Phase 1 · recruiting Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03422198Phase 3 · recruiting Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02364713Phase 2 · terminated MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05363631Phase 1/Phase 2 · active not recruiting Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07084909Phase 2/Phase 3 · withdrawn Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03260504Phase 1 · terminated Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04989959Phase 1 · recruiting [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04779151Phase 2 · terminated Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05795595Phase 1/Phase 2 · completed A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04370509Phase 2 · terminated Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06052852Phase 1 · terminated Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05119335Phase 1/Phase 2 · terminated A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05935748Phase 2 · terminated Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02111941early Phase 1 · completed Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07218692Phase 2 · not yet recruiting RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04169711Phase 1 · completed Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03438708Phase 2 · active not recruiting Prior Axitinib as a Determinant of Outcome of Renal Surgery · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06639074Phase 2 · recruiting Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01935934Phase 2 · completed Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06805825Phase 1 · recruiting A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04510597Phase 3 · recruiting Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06361810Phase 1/Phase 2 · withdrawn PSMA Therapy and Immunotherapy in Kidney Cancer · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07101900Phase 2 · enrolling by invitation 68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05585034Phase 1 · completed Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04458597NA · completed Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus. · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07097935Phase 1/Phase 2 · recruiting Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04627064Phase 1 · completed ABEMA Alone or in COMBO With MK-6482 · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05086692Phase 1/Phase 2 · recruiting A Beta-only IL-2 ImmunoTherapY Study · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05286294Phase 2 · active not recruiting Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04006405completed AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06393751Phase 1/Phase 2 · withdrawn Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06088134recruiting Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC) · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02713386Phase 1/Phase 2 · completed Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06976021Phase 2 · not yet recruiting Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06870279Phase 1 · not yet recruiting A Clinical Research of CD70-targeted CAR-NKT Cells (CGC738) Therapy in RCC · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04802876Phase 2 · active not recruiting Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04906382early Phase 1 · terminated Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05032040Phase 2 · active not recruiting A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03473730early Phase 1 · completed Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06791863completed Visceral Fat Area as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma: A Multicenter Study on Postoperative Survival · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06778538completed Evaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06775574completed Prognostic Significance of the Lung Immune Prognostic Index (LIPI) in Postoperative Clear Cell Renal Cell Carcinoma: a Multicenter Retrospective Cohort Study · condition mapped ALIAS · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03241745Phase 2 · completed A Study of Nivolumab in Selected Uterine Cancer Patients · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06750419Phase 3 · recruiting 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03634540Phase 2 · active not recruiting A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03015740Phase 1/Phase 2 · completed Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04227522Phase 3 · completed Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients · condition mapped CURATED_BROADER · 362 trials mapped (161 active) | — | — | Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05199272Phase 1/Phase 2 · active not recruiting A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06690697Phase 2 · recruiting Combination of Toripalimab and JS004 Therapy for ccRCC · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06519760NA · recruiting 68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 362 trials mapped (161 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |